Cellenkos, Inc. Initiates Phase 1 Clinical Trial of CK0801 for Treatment of Bone Marrow Failure Syndromes

June 4th 2019

HOUSTON, June 4, 2019 /PRNewswire/ -- Cellenkos, announced today the initiation of a Phase 1 Clinical Trial of CK0801, a first-in-class, allogeneic cord blood-derived T-regulatory cell product, for treatment of patients with bone marrow failure syndromes, including aplastic anemia, hypoplastic myelodysplasia, and primary myelofibrosis.  These syndromes are characterized by uncontrolled attack of disease-driving cytotoxic T-cells that lead to an inflammatory microenvironment and inhibition of normal blood cell production in the bone marrow.  CK0801 delivers healthy regulatory T-cells that home to sites of bone marrow inflammation and suppress the cytotoxic T-cells, allowing normalization of blood cell production.